Leukaemia - haematology - SA Health Approved Cancer Chemotherapy Protocol Register

Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukaemia
Protocol Administration at chemotherapy unit level Review Date
Acute lymphoblastic leukaemia ALL06 treatment overview INTERIM High August 2022
Acute Lymphoblastic leukaemia blinatumomab High December 2021
Acute lymphoblastic leukaemia dasatinib Low December 2021
Acute lymphoblastic leukaemia MRD+ blinatumomab High March 2022
Acute lymphoblastic leukaemia Ph- hyper CVAD part A High February 2024
Acute lymphoblastic leukaemia Ph- hyper CVAD part B High February 2024
Acute lymphoblastic leukaemia Ph- POMP maintenance therapy (mercaptopurine vinCRISTine methotrexate prednisolone) High February 2024
Acute lymphoblastic leukaemia Ph positive GRAAPH-2005 High February 2023
Acute lymphoblastic leukaemia Ph+ hyper CVAD part A and daSATtinib High February 2023
Acute lymphoblastic leukaemia Ph+ hyper CVAD part B and daSATinib High February 2023
Acute lymphoblastic leukaemia Ph+ maintenance therapy (daSATinib prednisolone vinCRISTine) Medium February 2023
Acute lymphoblastic leukaemia Ph+ hyper CVAD part A and imatinib High February 2023
Acute lymphoblastic leukaemia Ph+ hyper CVAD part B and imatinib High February 2023
Acute lymphoblastic leukaemia Ph+ maintenance therapy (imatinib prednisolone vinCRISTine) Medium February 2023
Acute lymphoblastic leukaemia ponatinib Low February 2023

Acute Myeloid Leukaemia

Acute myeloid leukaemia protocols
Protocol Administration at chemotherapy unit level Review date
Acute myeloid leukaemia azacitidine Low February 2025
Acute myeloid leukaemia azacitidine and venetoclax (via compassionate access program)
Medium August 2022
Acute myeloid leukaemia consolidation 5-2 ida (cytarabine and IDArubicin) High August 2021
Acute myeloid leukaemia consolidation HiDAC (cytarabine) High February 2021
Acute myeloid leukaemia consolidation IDAC - 1 (cytarabine) High February 2021
Acute myeloid leukaemia FLAG (fludarabine cytarabine and filgrastim) High August 2021
Acute myeloid leukaemia FLAG-Ida (fludarabine cytarabine IDArubicin and filgrastim) High August 2021
Acute myeloid leukaemia gilteritinib (via compassionate access program)
Low February 2022
Acute myeloid leukaemia induction 7-3 Ida (cytarabine and IDArubicin) High August 2021
Acute myeloid leukaemia consolidation HiDAC (cytarabine) with midostaurin High February 2023
Acute myeloid leukaemia induction 7-3 (cytarabine and DAUNOrubicin) with midostaurin High February 2023
Acute myeloid leukaemia midostaurin maintenance High February 2023
Acute myeloid leukaemia low dose cytarabine Low February 2024
Acute myeloid leukaemia low dose cytarabine and venetoclax (via compassionate access program)
Medium August 2022

Acute promyelocytic leukaemia

Acute promyelocytic leukaemia
Protocol Administration at chemotherapy unit level Review Date
Acute promyelocytic leukaemia APML4 induction High February 2023
Acute promyelocytic leukaemia APML4 consolidation 1 High February 2023
Acute promyelocytic leukaemia APML4 consolidation 2 High February 2023
Acute promyelocytic leukaemia APML4 maintenance Medium February 2023
Acute promyelocytic leukaemia standard risk (chemotherapy free) induction High February 2023
Acute promyelocytic leukaemia standard risk (chemotherapy free) consolidation High February 2023

Chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia
Protocol Administration at chemotherapy unit level Review Date
Chronic lymphocytic leukaemia acalabrutinib

Low February 2022
Chronic lymphocytic leukaemia bendamustine and rituximab
Medium February 2022
Chronic lymphocytic leukaemia FCR (fludarabine CYCLOPHOSPHamide RITUximab) Medium August 2022
Chronic lymphocytic leukaemia ibrutinib3
Low August 2022
Chronic lymphocytic leukaemia obinutuzumab and chlorambucil Medium August 2022
Chronic lymphocytic leukaemia venetoclax and obinutuzumab
Medium February 2022
Chronic lymphocytic leukaemia venetoclax and obinutuzumab Medium February 2022
Chronic lymphocytic leukaemia venetoclax and rituximab Medium cycle 1. Low cycle 2 onwards August 2022

*non-formulary drug

Chronic myeloid leukaemia

Chronic myeloid leukaemia
Protocol Administration at chemotherapy unit level Review Date
Chronic myeloid leukaemia dasatinib Low February 2025
Chronic myeloid leukaemia imatinib Low February 2025
Chronic myeloid leukaemia nilotinib Low February 2025
Chronic myeloid leukaemia ponatinib Low February 2025

Hairy cell leukaemia

Hairy cell leukaemia
Protocol Administration at chemotherapy unit level Review Date
Hairy cell leukaemia cladribine Medium August 2023

Myelodysplastic disorders

Myelodysplastic disorders
Protocol Administration at chemotherapy unit level Review Date
Myelodysplastic syndrome azacitidine Low February 2025
Primary myelofibrosis ruxolitinib Low February 2025

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.